Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals

Drug Profile

Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals

Alternative Names: C-10068; C-20081; C-21246; C-21359; CTP-221; D-apremilast; D-boceprevir; D-cilostazol; D-darunavir; D-iloprost; D-lenalidomide; D-linezolid; D-ranolazine

Latest Information Update: 13 Dec 2012

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Concert Pharmaceuticals; GlaxoSmithKline
  • Class Neuroprotectants; Organic deuterium compounds; Oxazolidinones; Small molecules; Sodium compounds; Sulfonamides; Synthetic prostaglandins
  • Mechanism of Action Angiogenesis inhibitors; GABA A receptor modulators; Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; HIV protease inhibitors; Immunomodulators; Interleukin 1 beta stimulants; Interleukin 10 stimulants; Partial fatty acid oxidation inhibitors; Platelet aggregation inhibitors; Prostacyclin agonists; Protein 30S ribosomal subunit inhibitors; Pyruvate dehydrogenase stimulants; Sigma-1 receptor agonists; Tumour necrosis factor inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; HIV infections; Inflammation; Kidney disorders; Methicillin-resistant Staphylococcus aureus infections; Neuropathic pain
  • Research Cardiovascular disorders; Epilepsy; Hepatitis C; Pulmonary arterial hypertension

Most Recent Events

  • 13 Dec 2012 Preclinical trials in Inflammation in USA (unspecified route)
  • 10 Dec 2012 Preclinical trials in Cancer in USA (unspecified route)
  • 10 Dec 2012 Pharmacodynamics data from a preclinical trial in Cancer presented at the 54th Annual Meeting of the American Society of Hematology (ASH-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top